For example, CREBBP/EP300 mutations frequently occur in primary and relapsed pediatric ALL [58,59,60,61,62,63,64], aggressive NK-cell leukemia (ANKL) [65], and chronic-phase chronic myeloid leukemia (CML-CP) [66]. Here, EP300 is linked to aggressive NK-cell leukemia.